Form 8-K

8-K — Drugs Made In America Acquisition Corp.

Accession: 0001213900-26-079678

Filed: 2026-07-20

Period: 2026-07-14

CIK: 0002028614

SIC: 6770 (BLANK CHECKS)

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — ea0298461-8k425_drugs.htm (Primary)

EX-2.1 — OMNIBUS AMENDMENT NO. 3 TO THE MERGER AGREEMENT (ea029846101ex2-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0298461-8k425_drugs.htm · Sequence: 1

false

0002028614

2026-07-14

0002028614

DMAA:UnitsEachConsistingOfOneOrdinaryShareParValue0.0001PerShareAndOneRightToReceiveOneeighth18OfOrdinaryShareMember

2026-07-14

0002028614

DMAA:OrdinarySharesMember

2026-07-14

0002028614

us-gaap:RightsMember

2026-07-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 14, 2026

DRUGS MADE IN AMERICA ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

Cayman Islands

001-42467

99-2394788

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

420 Lexington Avenue, Suite 1402

New York, NY 10170

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including

area code: (646) 726-7074

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Units, each consisting of one Ordinary Share, par value $0.0001 per share, and one Right to receive one-eighth (1/8) of an Ordinary Share

DMAAU

The Nasdaq Stock Market LLC

Ordinary Shares

DMAA

The Nasdaq Stock Market LLC

Rights

DMAAR

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

Amendment to Merger Agreement

As previously disclosed, on April 29, 2026, Drugs

Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company” or “DMAA”), entered into a

Definitive Merger Agreement (the “Merger Agreement”) with Power Analytics Global Corp, a Delaware corporation engaged in the

business of artificial intelligence, advanced analytics and quantum-resistant security solutions (“PAGC”). As previously disclosed,

the Merger Agreement was subsequently amended by Amendments No. 1 and No. 2. The Merger Agreement, as amended, provides for a business

combination pursuant to which PAGC will merge with and into the Company (or a wholly-owned subsidiary of the Company, as may be mutually

agreed by the parties), with the surviving entity continuing as the Company’s combined operating business following the closing

(the “Merger”). Following the consummation of the Merger, the surviving entity is intended to operate as a publicly traded

company on The Nasdaq Stock Market LLC.

On July 14, 2026, the Boards of Directors of the

Company and PAGC approved a third amendment to the Merger Agreement, a copy of which is filed as Exhibit 2.1 hereto and is incorporated

herein by reference. The purpose of Amendment No. 3 was as follows:

Former Sponsor/Founder Share Treatment

The Company agreed to: (i) cause the former sponsor

entity to forfeit not less than 50% of the founder shares held by it and cause the remainder to be subject to earnout vesting (50% vesting

if the closing price equals or exceeds $12.50 and 50% if it equals or exceeds $15.00, in each case for any 20 trading days within a 30-trading-day

period commencing after the closing, with unvested shares forfeited on the fifth anniversary of the closing), (ii) cause the sponsor’s

430,000 private placement rights to be surrendered for no consideration and the 45,092 ordinary shares corresponding to the unfunded portion

of the sponsor’s private placement subscription to be cancelled and (iii) obtain lock-up agreements from any other holders of founder

shares and to surrender any rights to receive shares of Company ordinary shares to the extent any are owned.

Treatment of Rights

The Company agreed, prior to or concurrently with

the mailing of the definitive proxy statement/prospectus and with PAGC’s consent, to commence one of (i) a cash tender offer for

all outstanding publicly held rights at a price of not less than $0.25 and not more than $0.35 per right, funded solely from sources other

than the Trust Account, (ii) an exchange offer on economically equivalent terms, or (iii) a consent solicitation to amend the Rights Agreement

to provide for cash settlement or a reduced conversion ratio; rights not tendered, exchanged or amended will remain outstanding and convert

in accordance with their terms.

Calculation of Merger Consideration

The parties also agreed to amend the provisions

of the Merger Agreement governing the exchange of Company shares and the exchange ratio so that all per-share computations are calculated

by reference to the Company’s fully diluted shares outstanding.

Financing

Certain other provisions were amended to permit

additional financings prior to the closing of the transaction.

Potential Additional Target; Contingent

Amendment No. 4

The parties are in negotiations with a third company

regarding a potential three-party business combination, pursuant to which such additional target would merge with a newly formed merger

subsidiary of the Company and become a wholly-owned subsidiary of the Company alongside PAGC, with the Company remaining the publicly

traded parent. Amendment No. 3 pre-approves the form of a contingent Amendment No. 4 to the Merger Agreement, which will become effective

only if, on or before September 30, 2026, a definitive letter of intent is executed, the additional target is designated by the parties

and executes a joinder, and the other conditions to effectiveness set forth therein are satisfied; if those conditions are not satisfied

by such date, the contingent amendment will be void and the parties will proceed with the business combination on the basis of the Merger

Agreement as amended.

Minimum Cash

The minimum-cash provisions of the Merger Agreement

were restated to provide for a target of $30,000,000 and a floor of $15,000,000, together with an adjustment grid specifying the valuation

and ownership consequences at defined available-cash levels.

Related-Party Matters

As previously disclosed, PAGC and BV Advisory

Partners, LLC are under common principal ownership, and the business combination accordingly constitutes an affiliated business combination

for purposes of the Company’s governing documents, IPO prospectus commitments, and applicable disclosure rules. Amendment No. 3

implements related-party protections in respect of this previously disclosed affiliation, including a condition to the Company’s

obligation to consummate the closing that its board of directors receive an opinion of an independent investment banking firm or independent

valuation firm to the effect that the business combination is fair, from a financial point of view, to the Company and/or its unaffiliated

shareholders, and a requirement that specified determinations under the amendment be made by, or at the direction of, the Company’s

independent and disinterested directors.

Additional Information

The foregoing description of the Merger Agreement

and the Amendments is qualified in its entirety by reference to the full text of Amendment No. 3, which is filed as Exhibit 2.1 to this

Current Report on Form 8-K and incorporated by reference herein. The representations, warranties and covenants of the parties contained

in the Merger Agreement and the Amendments have been made solely for the benefit of the parties thereto. In addition, such representations,

warranties and covenants (i) have been made only for purposes of the Merger Agreement and the Amendments, (ii) have been qualified by

confidential disclosures made in connection with the Merger Agreement, (iii) are subject to materiality qualifications contained in the

Merger Agreement which may differ from what may be viewed as material by investors, (iv) were made only as of the date of the Merger Agreement

(or such other date or dates as may be specified therein) and (v) have been included in the Merger Agreement for the purpose of allocating

risk between the contracting parties rather than establishing matters of fact. Accordingly, the Merger Agreement and the Amendments are

filed with this Current Report on Form 8-K only to provide investors with information regarding the terms of the Merger Agreement and

the Amendments, and not to provide investors with any other factual information regarding the Company or PAGC, their respective affiliates,

or their respective businesses. Investors should not rely on the representations, warranties and covenants or any descriptions thereof

as characterizations of the actual state of facts or condition of the Company, PAGC, their respective affiliates or their respective businesses.

Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the

Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking

statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act

of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,”

“forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,”

“seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not

statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the Merger and

the parties’ ability to consummate the transactions contemplated by the Merger Agreement, the expected ownership of the surviving

entity, the anticipated valuation of PAGC, the timing of closing, anticipated benefits of the Merger, and anticipated financial and operational

results of the surviving entity. These statements are based on various assumptions, whether or not identified in this Current Report on

Form 8-K, and on the current expectations of the management of DMAA and PAGC and are not predictions of actual performance. These forward-looking

statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as,

a guarantee, an assurance, a prediction or a definitive statement of fact or probability.

Actual events and circumstances are difficult

or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of DMAA and PAGC.

These forward-looking statements are subject to a number of risks and uncertainties, including, among others: (i) the risk that the Merger

may not be completed in a timely manner or at all; (ii) the risk that the Merger may not be completed by DMAA’s business combination

deadline; (iii) the failure to satisfy the conditions to the consummation of the Merger, including the approval of the Merger Agreement

by DMAA’s shareholders; (iv) failure to obtain a sufficient minimum cash amount at closing as a result of redemptions or otherwise;

(v) the inability to complete a PIPE financing or other capital raising transactions on terms reasonably acceptable to the parties or

at all; (vi) the risk that the contingent three-party structure described above does not become effective or is delayed; (vii) the effect

of the announcement or pendency of the Merger on PAGC’s business or employee relationships; (viii) the outcome of any legal proceedings

that may be instituted against DMAA or PAGC; (ix) the ability of the surviving entity to obtain or maintain the listing of its securities

on Nasdaq following the Merger; and (x) other risks and uncertainties indicated from time to time in DMAA’s filings with the SEC,

including those under “Risk Factors” in DMAA’s most recent Annual Report on Form 10-K and subsequent SEC filings, and

in the Registration Statement to be filed in connection with the Merger.

Nothing in this Current Report on Form 8-K should

be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the

contemplated results of such forward-looking statements will be achieved. Readers should not place undue reliance on forward-looking statements,

which speak only as of the date hereof. Neither DMAA nor PAGC undertakes any duty to update these forward-looking statements, except as

may be required by law.

No Offer or Solicitation

This Current Report on Form 8-K is not intended

to and does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the

Merger or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of DMAA, PAGC, the surviving

entity, or any of their respective affiliates. No offer of securities shall be made except by means of a prospectus meeting the requirements

of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. No offer, solicitation or sale

will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Important Information About the Merger and Where to Find It

In connection with the Merger, DMAA intends to

file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”), which will include a preliminary proxy

statement of DMAA and a prospectus relating to the offer of the surviving entity’s securities to be issued in connection with the

Merger. After the Registration Statement is declared effective by the SEC, DMAA will mail a definitive proxy statement/prospectus to its

shareholders. This Current Report on Form 8-K does not contain all of the information that should be considered concerning the Merger

and is not intended to form the basis of any investment decision or any other decision in respect of the Merger. DMAA’s shareholders

and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto

and the definitive proxy statement/prospectus, as well as other documents filed with the SEC in connection with the Merger, as these materials

will contain important information about DMAA, PAGC and the Merger. When available, the definitive proxy statement/prospectus and other

relevant materials for the Merger will be mailed to shareholders of DMAA as of a record date to be established for voting on the Merger.

Shareholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus

and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request

to: Drugs Made In America Acquisition Corp., 420 Lexington Avenue, Suite 1402, New York, NY 10170.

Participants in the Solicitation

DMAA, PAGC and their respective directors and

executive officers may be considered participants in the solicitation of proxies from DMAA’s shareholders with respect to the Merger.

A list of the names of those directors and executive officers and a description of their interests in DMAA will be contained in the Registration

Statement and the proxy statement/prospectus to be filed in connection with the Merger when it becomes available. Information regarding

the persons who may, under the rules of the SEC, be deemed participants in the solicitation of DMAA’s shareholders in connection

with the Merger will be set forth in the proxy statement/prospectus when it is filed with the SEC. You may obtain free copies of these

documents from the sources indicated above.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

2.1

Omnibus Amendment No. 3 to the Merger Agreement†

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

† Certain schedules and exhibits to

this Exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby agrees to furnish a copy of any omitted

schedule or exhibit to the SEC upon request.

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DRUGS MADE IN AMERICA ACQUISITION CORP.

Date: July 20, 2026

By:

/s/ Roger E. Bendelac

Name:

Roger E. Bendelac

Title:

Chief Executive Officer

EX-2.1 — OMNIBUS AMENDMENT NO. 3 TO THE MERGER AGREEMENT

EX-2.1

Filename: ea029846101ex2-1.htm · Sequence: 2

Exhibit 2.1

DMAA — Omnibus Amendment No. 3 (Re-Executed)

— Page 1

OMNIBUS AMENDMENT NO. 3

dated as of July 14, 2026

TO THE DEFINITIVE MERGER AGREEMENT

(which Definitive Merger Agreement is dated as

of April 29, 2026, as heretofore amended)

This OMNIBUS AMENDMENT NO. 3 (this “Amendment”)

is entered into as of July 14, 2026, by and between DRUGS MADE IN AMERICA ACQUISITION CORP., a Cayman Islands exempted company (“DMAA”

or the “Company”), and POWER ANALYTICS GLOBAL CORP, a Delaware corporation (“PAGC”). DMAA and PAGC are each a

“Party” and together the “Parties.” Capitalized terms used and not defined herein have the meanings given in the

Original Agreement (as defined below).

RECITALS

A. The Parties are parties to the Definitive Merger

Agreement, dated as of April 29, 2026, as amended by Amendment No. 1 thereto, dated as of April 30, 2026, and Amendment No. 2 thereto,

dated as of April 30, 2026 (as so amended, the “Original Agreement,” and as amended by this Amendment, the “Agreement”).

B. At an extraordinary general meeting held April

27, 2026, the Company’s shareholders approved an amendment to the Company’s charter permitting up to twelve one-month extensions

of the business combination deadline to April 29, 2027; in connection therewith, holders of 9,440,230 public shares redeemed for $99,336,016.67,

following which 24,276,913 ordinary shares remain outstanding, of which 13,559,770 are public shares.

C. The Parties desire to fix the Company’s

capitalization prior to the filing of the Registration Statement by resolving the Company’s founder shares, rights, representative

shares, and other fixed and contingent issuances; to restate the financing and minimum-cash architecture; and to establish the pre-Closing

timeline.

D. The Parties are in advanced negotiations with

a third company regarding a three-party combination, on a framework reflected in a draft letter of intent circulated July 1, 2026, with

execution of a definitive letter of intent expected during the week of July 13, 2026 (as executed, whenever executed, the “LOI”).

Such third company (the “Additional Target”) is not identified by name in this Amendment; it shall be identified exclusively

by a joint written designation delivered by the Parties pursuant to Section 4.1 (the “Designation Notice”). Neither this Amendment

nor any obligation hereunder is conditioned on execution of the LOI, and the Parties desire to pre-approve the form of Amendment No. 4

attached as Annex A hereto on a contingent-effectiveness basis, without conditioning any other provision of this Amendment thereon.

E. PAGC and BV Advisory Partners, LLC (“BV”)

— the investor holding convertible notes of the Company and entitled to not less than 40% of sponsor-level economics under the Definitive

Interim Investment and Sponsor Transition Agreement dated March 23, 2026 — are under common principal ownership, as was fully disclosed

to and considered by the Company’s board of directors prior to its approval of the March 23, 2026 transition agreement and the Original

Agreement. The Parties acknowledge that the Business Combination accordingly constitutes an affiliated business combination for purposes

of the Company’s governing documents, IPO prospectus commitments, and applicable disclosure rules, and this Amendment implements

the protections of Section 6.5 in respect thereof.

NOW, THEREFORE, in consideration of the mutual

covenants herein and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the Parties agree

as follows:

ARTICLE 1 — CERTAIN DEFINITIONS

1.1 Definitions. As used in the Agreement:

“Company Fully Diluted Share Number” means, as of immediately prior to the Effective Time: (i) the public shares outstanding

after giving effect to all redemptions; plus (ii) the founder shares outstanding after giving effect to all forfeitures and surrenders

pursuant to the Support Agreements; plus (iii) the 430,000 private placement shares (less the 45,092 shares cancelled pursuant to Section

2.1(c)); plus (iv) the 230,000 representative shares; plus (v) the 200,000 shares issued March 11, 2025; plus (vi) the 425,000 Executive

Shares; plus (vii) the ordinary shares issuable upon conversion of rights that remain outstanding as of the Effective Time; plus (viii)

the ordinary shares issuable upon conversion of any convertible notes and working capital loans outstanding at the Effective Time (calculated

at the price required by their terms, using the Reference Price for any market-price mechanic). “Executive Shares” means the

250,000 ordinary shares issuable in respect of Roger E. Bendelac (via Aleutian Equity Holdings LLC) and the 175,000 ordinary shares issuable

in respect of Saleem Elmasri (via Titan Advisory Services LLC), in each case as previously approved by the Company’s board of directors,

governed exclusively by the executed agreements disclosed in the Company’s Form 8-K dated April 22, 2026, and referenced in this

Amendment solely for share-count purposes. “Reference Price” means $10.00 per ordinary share. “Structure Election Date”

means September 30, 2026. “Support Agreements” means the Sponsor Support and Surrender Agreement and the Founder-Holder Support

Agreements described in Sections 2.1 and 2.2.

ARTICLE 2 — CAPITALIZATION RESOLUTION

2.1 Sponsor Support and Surrender Agreement.

Within 30 days after the date hereof, the Company shall enter into, and shall use reasonable best efforts to cause Drugs Made In America

Acquisition LLC (the “Sponsor”) and Lynn Stockwell to enter into, a Sponsor Support and Surrender Agreement in form reasonably

acceptable to PAGC providing for: (a) the surrender and forfeiture to the Company, for no consideration and effective as a contribution

to the Company’s capital as a matter of Cayman Islands law, of not less than fifty percent (50%) of the ordinary shares held by

the Sponsor; (b) earnout vesting of the remainder of the Sponsor’s ordinary shares (50% vesting if the closing price equals or exceeds

$12.50, and 50% if it equals or exceeds $15.00, in each case for any 20 trading days within a 30-trading-day period commencing after the

Closing, with unvested shares forfeited on the fifth anniversary of the Closing); (c) the cancellation and surrender of the 45,092 ordinary

shares corresponding to the unfunded portion of the Sponsor’s private placement subscription; (d) the surrender for no consideration

of the Sponsor’s 430,000 private placement rights; and (e) voting, lock-up, and cooperation covenants consistent with the Sponsor’s

standstill, non-voting and cooperation acknowledgment dated March 18, 2026.

2.2 Founder-Holder Support Agreements.

Within 45 days after the date hereof, the Company shall use reasonable best efforts to obtain Founder-Holder Support Agreements, in form

reasonably acceptable to PAGC, from holders of not less than 80% of the founder shares not held by the Sponsor, each providing for: (a)

forfeiture and/or earnout vesting of not less than fifty percent (50%) of such holder’s founder shares on the mechanics of Section

2.1(b); (b) an agreement to vote all shares held in favor of the Business Combination; (c) confirmation of existing lock-up and redemption-waiver

obligations; and (d) the surrender for no consideration of any rights held by such holder.

2.3 Rights Resolution. (a) Promptly following

the date hereof, the Company shall obtain and deliver to PAGC the Rights Agreement and a determination of its amendment requirements (the

“Rights Route Determination”). (b) At such time as the Company’s board of directors determines, having regard to the

availability of funding from sources other than the Trust Account and the status of public disclosure — but in any event prior to

or concurrently with the mailing of the definitive proxy statement/prospectus for the Business Combination — the Company shall,

at its election with PAGC’s consent (not to be unreasonably withheld, conditioned or delayed), commence one of: (i) a cash tender

offer for all outstanding publicly held rights at a price of not less than $0.25 and not more than $0.35 per right, conducted in accordance

with Rule 13e-4 and Regulation 14E and funded solely from sources other than the Trust Account; (ii) an exchange offer on economically

equivalent terms; or (iii) a consent solicitation to amend the Rights Agreement to provide for cash settlement or a reduced conversion

ratio, together with a customary consent fee; any such consent solicitation may be conducted concurrently with, and as part of, the Registration

Statement and proxy process for the Business Combination, with any resulting amendment to the Rights Agreement conditioned upon, and effective

only at, the Closing — such that the requisite consent of rights holders under the Rights Agreement is obtained in connection with,

and as a practical condition of, the Business Combination, it being acknowledged that no amendment of the rights shall be effected without

the consent of holders required by the Rights Agreement, and that rights not tendered, exchanged, or amended shall remain outstanding

and convert in accordance with their terms. (c) Notwithstanding the foregoing, the Company shall not commence any tender offer, exchange

offer, or consent solicitation under this Section 2.3 at any time when the Company possesses material nonpublic information concerning

the Business Combination (including the matters described in Recital D) that has not been publicly disclosed, and the offer documents

shall include all information required by applicable law. (d) The Company shall keep PAGC reasonably informed of participation and shall

not increase the consideration beyond the stated maximum without PAGC’s consent. (e) It shall be a condition to PAGC’s obligation

to consummate the Closing that rights remaining outstanding as of the Effective Time are convertible into no more than such number of

ordinary shares as PAGC shall have approved in writing in connection with the commencement of the applicable offer or solicitation (or,

if none is commenced, as the Parties shall agree in connection with the mailing of the definitive proxy statement/prospectus), which approval

and agreement shall not be unreasonably withheld.

2.4 Underwriter Arrangements. The Company

shall use reasonable best efforts to enter into, within 45 days after the date hereof, a side letter or amendment with Clear Street LLC

providing for: (a) a lock-up of the 230,000 representative shares on terms no less restrictive than the founder lock-up, together with

such forfeiture or earnout of such shares, if any, as may be negotiated; (b) a restatement (and any negotiated reduction or share-settlement)

of the deferred underwriting fee, currently $6,900,000 subject to the redemption adjustment (approximately $6.19 million as of the date

hereof); and (c) coordination of the foregoing with Clear Street’s engagement as placement agent for the PIPE.

2.5 Executive Shares; Fixed Issuances.

The Executive Shares were previously approved and disclosed, are governed exclusively by their existing executed agreements, and require

no further approval or action under this Amendment; they are included in Schedule 2.5 and in the Company Fully Diluted Share Number solely

so that the share count is complete. The Company represents that Schedule 2.5 sets forth its complete capitalization as of the date hereof,

including the March 2025 issuance of 200,000 shares and the 230,000 representative shares, and shall deliver an updated Schedule 2.5,

certified by an authorized officer of the Company and reconciled to the records of its transfer agent, not later than five Business Days

prior to the Closing and again immediately prior to the Effective Time.

2.6 Consideration True-Up. The provisions

of the Original Agreement governing the calculation of the merger consideration and exchange ratio are amended so that all per-share computations

and the aggregate share consideration issuable to PAGC equityholders are calculated by reference to the Company Fully Diluted Share Number

and the Reference Price, such that the equity value ascribed to PAGC under the Agreement (or, if the Contingent Amendment becomes effective,

the combined framework therein) is issued against the Company’s true fully diluted capitalization at Closing.

ARTICLE 3 — FINANCING; MINIMUM CASH; TRUST

3.1 Permitted Financings. Notwithstanding

anything in the Original Agreement, the following shall be permitted and shall not breach any exclusivity, no-shop, or capital-raising

restriction: (a) the convertible notes issued and issuable to BV Advisory Partners, LLC under the Definitive Interim Investment and Sponsor

Transition Agreement dated March 23, 2026 (up to $500,000, convertible at a 35% discount following the Closing), provided that any “sponsor-level

economics” payable to such investor shall be determined net of all forfeitures and surrenders effected under Article 2, and that

all determinations of the Company with respect to such investor’s arrangements shall be made in accordance with Section 6.5(b);

(b) one or more private placements of equity or equity-linked securities of the Company or the post-combination company in an aggregate

amount of up to $150,000,000, placed by Clear Street LLC and/or such additional placement agents as the Company and PAGC approve, and

direct investments by strategic or institutional investors in connection therewith, subject in each case to customary confidentiality

and wall-crossing procedures for any investor brought over the wall prior to public announcement; (c) working capital loans convertible

into units at $10.00 per unit up to $1,500,000 as disclosed in the Company’s Annual Report; and (d) at the Company’s option

and without any obligation or assumption, a pre-PIPE convertible note facility of up to $5,000,000 (minimum initial closing $1,500,000;

interest capitalized into principal), it being acknowledged that such facility has not been consummated, may not occur, and shall not

be assumed in any covenant, condition, or computation under the Agreement.

3.2 Minimum Cash. The minimum-cash provisions

of the Original Agreement are restated as set forth on Schedule 3.2, which shall provide: a target of $30,000,000 and a floor of $15,000,000;

an adjustment grid specifying the valuation and ownership consequences at defined available-cash levels; and that “Available Closing

Cash” counts Trust Account proceeds net of final redemptions, PIPE proceeds actually funded, any agreed reduction of the deferred

underwriting fee, and proceeds of the facility described in Section 3.1(d) only if and to the extent actually funded at or prior to Closing.

The grid and the floor shall be satisfiable without any proceeds of such facility.

3.3 Extension Deposits. The Parties acknowledge

that the Company’s shareholders approved, on April 27, 2026, up to twelve one-month extensions of the business combination deadline

through April 29, 2027, with no further shareholder authorization required, upon a monthly deposit of the lesser of $300,000 or $0.04

per non-redeemed public share. Nothing in this Section revisits that authorization. This Section addresses funding only: the Company shall

maintain, and upon PAGC’s reasonable request evidence, a committed source for such deposits through the Outside Date that does not

assume the facility described in Section 3.1(d).

3.4 Acknowledgment of Redemption Baseline.

The Parties acknowledge the redemption described in Recital B, and all references in the Original Agreement to the Company’s public

shares are conformed to a baseline of 13,559,770 public shares, subject to further redemptions in connection with the Business Combination

vote.

ARTICLE 4 — CONTINGENT AMENDMENT NO. 4

(ADDITIONAL TARGET)

4.1 Pre-Approval; Contingent Effectiveness.

The Parties approve the form of Amendment No. 4 to the Agreement attached as Annex A (the “Contingent Amendment”). The Contingent

Amendment shall become effective if, and only if, on or before the Structure Election Date, (a) the LOI has been executed and the Parties

have delivered the Designation Notice identifying the Additional Target by its legal name, (b) the Additional Target and each merger subsidiary

contemplated thereby execute and deliver the joinder attached to the Contingent Amendment, and (c) each condition to effectiveness stated

therein is satisfied. If the Contingent Amendment has not become effective by the Structure Election Date, it shall be void ab initio

without any action of the Parties, no Party shall have any obligation thereunder, and the Parties shall proceed with the Business Combination

on the basis of the Agreement without regard thereto.

4.2 No Delay. No obligation under this

Amendment or the Original Agreement — including the Registration Statement filing covenant in Section 5.1 — shall be delayed,

conditioned, or excused by reference to the Contingent Amendment or to any negotiation with the Additional Target.

ARTICLE 5 — TIMELINE

5.1 Registration Statement. The Company

shall file the Registration Statement on Form S-4 within 45 days after the later of (a) the date hereof and (b) receipt of the audited

financial statements of PAGC required for inclusion therein (or, solely if the Contingent Amendment has become effective, the financial

statements required for the structure elected thereunder); provided that if the Contingent Amendment has not become effective by the Structure

Election Date, the Registration Statement shall be filed on the basis of the Agreement without further delay.

5.2 Outside Date. The Outside Date is February

26, 2027. Each Party shall use reasonable best efforts to consummate the Closing prior to the Outside Date, and in any event prior to

April 29, 2027.

ARTICLE 6 — HOUSEKEEPING

6.1 Schedules; Representations. The disclosure

schedules are updated as attached; each Party’s representations and warranties are brought down to the date hereof, subject to such

schedules, including the Company’s disclosure of the Sponsor’s default and standstill, the working-capital withdrawals, going-concern

qualification, and material weaknesses.

6.2 Registration Rights. At the Closing,

the Company’s registration rights agreement shall be amended to add the PAGC equityholders, BV Advisory Partners, LLC, and the recipients

of the Executive Shares (and, if the Contingent Amendment becomes effective, the equityholders of the Additional Target).

6.3 Prior Drafts Superseded. Any draft

three-party amendment circulated prior to the date hereof (including the draft circulated in May 2026), and the version of this Omnibus

Amendment No. 3 executed prior to the date hereof (if any), are superseded in their entirety by this Amendment and shall be of no effect.

6.4 Conformed Copy. Counsel shall prepare a single conformed

copy of the Agreement as amended through this Amendment for use as an exhibit to the Registration Statement.

6.5 Related-Party Protections. In light

of the common principal ownership described in Recital E: (a) it shall be a condition to the Company’s obligation to consummate

the Closing that the Company’s board of directors shall have received an opinion of an independent investment banking firm or independent

valuation firm, in customary form, to the effect that the Business Combination is fair, from a financial point of view, to the Company

(and/or its unaffiliated shareholders), and the Company shall engage such firm promptly following the date hereof; (b) each determination,

consent, waiver, or amendment on the part of the Company under Sections 2.1 through 2.4, Section 2.6, Section 3.1(a), Section 3.2, and

Article 4 shall be made by, or at the direction of, the Company’s independent and disinterested directors; (c) PAGC shall deliver,

within 10 Business Days, a schedule of all direct and indirect ownership, economic, and contractual relationships between (x) PAGC and

its officers, directors, and 5% holders and (y) BV, its principals, and their affiliates, which schedule shall be updated through Closing

and disclosed in the Registration Statement; (d) PAGC shall promptly inform the Company whether the Additional Target, or any of its officers,

directors, or significant holders, has any affiliation with PAGC, BV, or their respective principals, and any such affiliation shall be

addressed in the fairness opinion under clause (a) and disclosed; and (e) the affiliation described in Recital E shall be disclosed in

the Form 8-K reporting this Amendment and prominently in the Registration Statement.

ARTICLE 7 — MISCELLANEOUS

7.1 Effect. Except as expressly amended

hereby, the Original Agreement remains in full force and effect. This Amendment is governed by the law governing the Original Agreement

(Delaware, per Amendment No. 1). This Amendment may be executed in counterparts, including by electronic signature, each of which is an

original and all of which together constitute one instrument.

IN WITNESS WHEREOF, the Parties have executed this Amendment as of

the date first written above.

DRUGS MADE IN AMERICA ACQUISITION CORP.

By:

Name:

Roger E. Bendelac

Title:

Chief Executive Officer

POWER ANALYTICS GLOBAL CORP

By:

Name:

Keith Barksdale

Title:

Executive Chairman

ANNEX A

FORM OF AMENDMENT NO. 4 TO THE DEFINITIVE MERGER

AGREEMENT

(Contingent — effective only upon joinder

by the Additional Target on or before the Structure Election Date, per Article 4 of Omnibus Amendment No. 3. To be conformed by counsel

to the LOI as executed; the economic framework below reflects the status of negotiations as of the date of Omnibus Amendment No. 3 and

adjusts automatically to the executed LOI, subject to Section 4 hereof.)

This AMENDMENT NO. 4 to the Definitive Merger

Agreement dated as of April 29, 2026, as amended (“Amendment No. 4”), is entered into by and between DMAA and PAGC and, upon

execution of the Joinder below, the Additional Target (the entity identified in the Designation Notice delivered pursuant to Section 4.1

of Omnibus Amendment No. 3, whose legal name shall be inserted at joinder), PAGC Merger Sub, Inc., and a second Delaware merger subsidiary

of DMAA to be formed for the Additional Target merger (“Merger Sub II”).

1. Restructuring. The Business Combination

is restructured such that DMAA remains the surviving publicly traded Cayman Islands parent, and at the Closing (a) PAGC merges with PAGC

Merger Sub and survives as a wholly-owned Delaware subsidiary of DMAA, and (b) the Additional Target merges with Merger Sub II and survives

as a wholly-owned Delaware subsidiary of DMAA, in each case by reverse triangular merger.

2. Consideration. The Business Combination

reflects a combined equity value of $3,000,000,000 for PAGC and the Additional Target, taken together, allocated between PAGC and the

Additional Target in the respective percentages set forth in the executed LOI. The Parties acknowledge that such allocation remains under

active negotiation as of the date of Omnibus Amendment No. 3 and is not fixed by this Amendment No. 4; upon execution of the LOI, this

Section shall be conformed to the allocation set forth therein without further action of the Parties. The consideration is payable in

DMAA ordinary shares at the Reference Price of $10.00 per share, in each case subject to the adjustment and true-up mechanics of the Agreement

(including Section 2.6 of Omnibus Amendment No. 3); provided that if the executed LOI reflects a combined equity value other than $3,000,000,000,

such change shall require the further approval of the DMAA board of directors as a condition to effectiveness under Section 4.

3. Dual Path. If the Additional Target

achieves Audit Readiness (PCAOB-audited financial statements for all periods required for inclusion in the Registration Statement) on

or before the Path Determination Date (September 30, 2026), both mergers close simultaneously (Path A). If not, the PAGC merger closes

first as the initial Business Combination, and the Additional Target merger closes thereafter under a cross-conditioned agreement on the

terms hereof (Path B).

4. Conditions to Effectiveness. This Amendment

No. 4 is of no force or effect unless and until, on or before the Structure Election Date: (a) the LOI has been executed and the Designation

Notice delivered, and the Additional Target and both merger subsidiaries execute the Joinder (inserting the Additional Target’s

legal name); (b) the boards of directors of each Party and of the Additional Target have approved this Amendment No. 4 (in the case of

DMAA, with such fairness analysis as the DMAA board deems appropriate for the revised valuation framework); (c) the parties have agreed

a reconciled presentation of PAGC’s projected financial information for use in the Registration Statement; and (d) the affiliation

inquiry under Section 6.5(d) of Omnibus Amendment No. 3 has been completed with respect to the Additional Target and, if any affiliation

with PAGC, BV Advisory Partners, LLC, or their principals exists, the fairness opinion under Section 6.5(a) covers the combined transaction.

5. Miscellaneous. Except as amended hereby, the

Agreement (including Omnibus Amendment No. 3) remains in full force and effect. Delaware law governs. Counterparts and electronic signatures

permitted.

SIGNATURE PAGES TO FORM OF AMENDMENT NO. 4

— DO NOT EXECUTE ON THE DATE OF OMNIBUS AMENDMENT NO. 3. The signature blocks below — including those of DMAA and PAGC

— are to be executed only upon joinder of the Additional Target pursuant to Article 4 of Omnibus Amendment No. 3. Approval of this

form is given by execution of Omnibus Amendment No. 3 itself; no signature below is required or requested at the execution of Omnibus

Amendment No. 3.

JOINDER — By executing below, the

Additional Target and each merger subsidiary joins and agrees to be bound by the Agreement as amended, including this Amendment No. 4.

DRUGS MADE IN AMERICA ACQUISITION CORP. (execute at joinder only)

By:

Name:

Roger E. Bendelac

Title:

Chief Executive Officer

POWER ANALYTICS GLOBAL CORP (execute at joinder only)

By:

Name:

Title:

[LEGAL NAME OF ADDITIONAL TARGET] (upon joinder)

By:

Name:

Title:

PAGC MERGER SUB, INC.; MERGER SUB II (upon joinder)

By:

Name:

Title:

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jul. 14, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 14, 2026

Entity File Number

001-42467

Entity Registrant Name

DRUGS MADE IN AMERICA ACQUISITION CORP.

Entity Central Index Key

0002028614

Entity Tax Identification Number

99-2394788

Entity Incorporation, State or Country Code

Entity Address, Address Line One

420 Lexington Avenue

Entity Address, Address Line Two

Suite 1402

Entity Address, City or Town

New York

Entity Address, State or Province

Entity Address, Postal Zip Code

10170

City Area Code

646

Local Phone Number

726-7074

Written Communications

true

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Units, each consisting of one Ordinary Share, par value $0.0001 per share, and one Right to receive one-eighth (1/8) of an Ordinary Share

Title of 12(b) Security

Units, each consisting of one Ordinary Share, par value $0.0001 per share, and one Right to receive one-eighth (1/8) of an Ordinary Share

Trading Symbol

DMAAU

Security Exchange Name

NASDAQ

Ordinary Shares

Title of 12(b) Security

Ordinary Shares

Trading Symbol

DMAA

Security Exchange Name

NASDAQ

Rights [Member]

Title of 12(b) Security

Rights

Trading Symbol

DMAAR

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=DMAA_UnitsEachConsistingOfOneOrdinaryShareParValue0.0001PerShareAndOneRightToReceiveOneeighth18OfOrdinaryShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=DMAA_OrdinarySharesMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_RightsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: